Literature DB >> 2117641

Selective expansion of T cells expressing V beta 2 in toxic shock syndrome.

Y Choi1, J A Lafferty, J R Clements, J K Todd, E W Gelfand, J Kappler, P Marrack, B L Kotzin.   

Abstract

Infection with Staphylococcus aureus and the production of toxic shock syndrome toxin-1 (TSST-1) have been implicated in the pathogenesis of toxic shock syndrome. Previous in vitro studies have demonstrated that TSST-1 is a powerful but selective stimulator of human T cells, and that the majority of activated cells express the TCR V beta 2 gene segment. We therefore studied patients with toxic shock syndrome using a modification of the PCR to determine if expansion of V beta 2+ T cells is a marker of the in vivo disease process. Five of eight patients studied demonstrated markedly elevated levels of circulating V beta 2+ T cells, whereas none showed significantly elevated levels of T cells expressing other V beta gene segments. The results suggest that toxin-mediated T cell activation, which involves a large fraction of the human T cell repertoire, may be critical in the pathogenesis of this disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2117641      PMCID: PMC2188536          DOI: 10.1084/jem.172.3.981

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  16 in total

Review 1.  Mediators in the pathogenesis of toxic shock syndrome: overview.

Authors:  J Parsonnet
Journal:  Rev Infect Dis       Date:  1989 Jan-Feb

2.  Interaction of Staphylococcus aureus toxin "superantigens" with human T cells.

Authors:  Y W Choi; B Kotzin; L Herron; J Callahan; P Marrack; J Kappler
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

Review 3.  Toxic shock syndrome.

Authors:  J K Todd
Journal:  Clin Microbiol Rev       Date:  1988-10       Impact factor: 26.132

4.  The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells.

Authors:  E R Gaynor; L Vitek; L Sticklin; S P Creekmore; M E Ferraro; J X Thomas; S G Fisher; R I Fisher
Journal:  Ann Intern Med       Date:  1988-12-15       Impact factor: 25.391

5.  A new staphylococcal enterotoxin, enterotoxin F, associated with toxic-shock-syndrome Staphylococcus aureus isolates.

Authors:  M S Bergdoll; B A Crass; R F Reiser; R N Robbins; J P Davis
Journal:  Lancet       Date:  1981-05-09       Impact factor: 79.321

6.  Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome.

Authors:  P M Schlievert; K N Shands; B B Dan; G P Schmid; R D Nishimura
Journal:  J Infect Dis       Date:  1981-04       Impact factor: 5.226

7.  Nonmenstrual toxic shock syndrome: a review of 130 cases.

Authors:  A L Reingold; N T Hargrett; B B Dan; K N Shands; B Y Strickland; C V Broome
Journal:  Ann Intern Med       Date:  1982-06       Impact factor: 25.391

8.  Toxic-shock syndrome in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 cases.

Authors:  K N Shands; G P Schmid; B B Dan; D Blum; R J Guidotti; N T Hargrett; R L Anderson; D L Hill; C V Broome; J D Band; D W Fraser
Journal:  N Engl J Med       Date:  1980-12-18       Impact factor: 91.245

9.  Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention.

Authors:  J P Davis; P J Chesney; P J Wand; M LaVenture
Journal:  N Engl J Med       Date:  1980-12-18       Impact factor: 91.245

10.  V beta-specific stimulation of human T cells by staphylococcal toxins.

Authors:  J Kappler; B Kotzin; L Herron; E W Gelfand; R D Bigler; A Boylston; S Carrel; D N Posnett; Y Choi; P Marrack
Journal:  Science       Date:  1989-05-19       Impact factor: 47.728

View more
  88 in total

Review 1.  Exotoxins of Staphylococcus aureus.

Authors:  M M Dinges; P M Orwin; P M Schlievert
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

2.  A persistent T cell expansion in the peripheral blood of a normal adult male: a new clinical entity?

Authors:  J Grunewald; M Jeddi-Tehrani; H Dersimonian; R Andersson; H Wigzell
Journal:  Clin Exp Immunol       Date:  1992-08       Impact factor: 4.330

Review 3.  Superantigens: biology, immunology, and potential role in disease.

Authors:  C G Drake; B L Kotzin
Journal:  J Clin Immunol       Date:  1992-05       Impact factor: 8.317

4.  Repertoire of transcribed peripheral blood T-cell receptor beta chain variable-region genes in acute rheumatic fever.

Authors:  W G Abbott; M A Skinner; L Voss; D Lennon; P L Tan; J D Fraser; I J Simpson; R Ameratunga; A Geursen
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

Review 5.  Staphylococcal manipulation of host immune responses.

Authors:  Vilasack Thammavongsa; Hwan Keun Kim; Dominique Missiakas; Olaf Schneewind
Journal:  Nat Rev Microbiol       Date:  2015-09       Impact factor: 60.633

Review 6.  Intravenous immunoglobulin therapy in vasculitis: speculation or evidence?

Authors:  Peer Malte Aries; Bernhard Hellmich; Wolfgang Ludwig Gross
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

7.  Prognostic usefulness of lymphocyte V beta receptor determination in toxic shock syndrome.

Authors:  Reiko Ohashi; Junji Takaya; Shoji Tsuji; Fumiko Yamato; Masafumi Hasui; Yoh Kinoshita; Yohnosuke Kobayashi
Journal:  Eur J Pediatr       Date:  2005-07-27       Impact factor: 3.183

8.  Dominant clonotypes in the repertoire of peripheral CD4+ T cells in rheumatoid arthritis.

Authors:  J J Goronzy; P Bartz-Bazzanella; W Hu; M C Jendro; D R Walser-Kuntz; C M Weyand
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808

9.  T cell receptor (TCR) V gene usage in patients with systemic necrotizing vasculitis.

Authors:  R Giscombe; J Grunewald; S Nityanand; A K Lefvert
Journal:  Clin Exp Immunol       Date:  1995-08       Impact factor: 4.330

10.  Superantigenic properties of the group A streptococcal exotoxin SpeF (MF).

Authors:  A Norrby-Teglund; D Newton; M Kotb; S E Holm; M Norgren
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.